Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy. The company's biosimilar programs comprise M923, a biosimilar of HUMIRA for the treatment of patients with rheumatoid arthritis, crohn's disease, ulcerative colitis, and psoriasis; and M710, a biosimilar of EYLEA for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema (DME), and diabetic retinopathy in patients with DME. Its complex generics programs include Enoxaparin sodium injection, a generic version of LOVENOX that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing forms of multiple sclerosis; and GLATOPA, a generic version of three-times-weekly COPAXONE. The company has collaboration and license agreements with Sandoz AG, Mylan Ireland Limited, and CSL Behring Recombinant Facility AG. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Phone617-491-9700
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$75.59 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/14/2019 (Estimated)
OptionableOptionable
Momenta Pharmaceuticals (NASDAQ:MNTA) Frequently Asked Questions
What is Momenta Pharmaceuticals' stock symbol?
Momenta Pharmaceuticals trades on the NASDAQ under the ticker symbol "MNTA."
How were Momenta Pharmaceuticals' earnings last quarter?
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) posted its quarterly earnings data on Friday, February, 22nd. The biotechnology company reported ($0.07) EPS for the quarter, topping analysts' consensus estimates of ($0.46) by $0.39. The biotechnology company earned $42.80 million during the quarter, compared to analyst estimates of $17.11 million. Momenta Pharmaceuticals had a negative net margin of 232.92% and a negative return on equity of 47.74%. The company's revenue was down 33.7% on a year-over-year basis. During the same quarter last year, the business posted $0.18 EPS. View Momenta Pharmaceuticals' Earnings History.
When is Momenta Pharmaceuticals' next earnings date?
What price target have analysts set for MNTA?
5 brokerages have issued 12 month price targets for Momenta Pharmaceuticals' shares. Their predictions range from $14.15 to $35.00. On average, they anticipate Momenta Pharmaceuticals' share price to reach $23.5375 in the next year. This suggests a possible upside of 78.3% from the stock's current price. View Analyst Price Targets for Momenta Pharmaceuticals.
What is the consensus analysts' recommendation for Momenta Pharmaceuticals?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Momenta Pharmaceuticals in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Momenta Pharmaceuticals.
What are Wall Street analysts saying about Momenta Pharmaceuticals stock?
Here are some recent quotes from research analysts about Momenta Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Momenta’s fourth-quarter results were better than expected. Last year was a transformational one for Momenta as it undertook a strategic review with the goal to shift focus from its dual focus on novel drugs and biosimilars to the discovery and development of novel drugs to treat rare, immune-mediated disorders. Momenta will now advance only two late-stage biosimilar assets, M923, its wholly-owned proposed biosimilar to Humira, and M710, its proposed biosimilar to Eylea. Earlier, the FDA approval of Glatopa 40 mg relieved Momenta, but competition was stiff as Mylan had already won the FDA’s approval for a generic version of Teva Pharmaceuticals’ Copaxone 40 mg, thereby limiting gains. Hence, cost savings from the restructuring plan should enable Momenta to develop novel drug candidates. We expect investors to focus on further updates from the candidate in development as the year progresses." (3/5/2019)
- 2. Stifel Nicolaus analysts commented, "We remain positive on the stock as we believe very little is currently being priced in for MNTA’s M281 program, which we view as mechanistically de-risked and, based on our prior research into the CK/albumin controversies, to be safe. With the first set of proof-of-concept (POC) data expected in 1H-to-mid-2020 for M254 and M281, we believe the stock should begin to work in anticipation of these results and think shares could inflect to ~$40, if they are positive. 2 study in myasthenia gravis (MG) is underway, with results expected in mid-2020. MNTA’s CEO indicated he had just returned from initiating a site for the Phase 2 trial for M281 in MG and, while he acknowledged the heightened competition for MG patients given the increased clinical activity in the space – i.e." (2/22/2019)
- 3. Cantor Fitzgerald analysts commented, ". Post 4Q18, we reiterate our Neutral rating and our 12-month price target of $16. We view the company’s novel pipeline as potentially blockbuster, although safety concerns raised over the Phase 1 data and a lack of any significant catalysts in 2019 keep us on the sidelines. We could be more constructive on MNTA stock if the company is able to advance its early-stage, novel drugs and show positive efficacy and safety data. We believe the concerns around M281 Phase 1 creatine kinase (CK) and albumin data may turn out to be overdone; however, we would like to see more data on this before moving off the sidelines." (2/22/2019)
Has Momenta Pharmaceuticals been receiving favorable news coverage?
Headlines about MNTA stock have trended positive on Tuesday, according to InfoTrie Sentiment. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Momenta Pharmaceuticals earned a media sentiment score of 2.2 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the immediate future.
Who are some of Momenta Pharmaceuticals' key competitors?
Some companies that are related to Momenta Pharmaceuticals include Spark Therapeutics (ONCE), argenx (ARGX), Ablynx (ABLYF), China Biologic Products (CBPO), Allogene Therapeutics (ALLO), Repligen (RGEN), Acceleron Pharma (XLRN), Halozyme Therapeutics (HALO), Aerie Pharmaceuticals (AERI), Regenxbio (RGNX), Crispr Therapeutics (CRSP), Denali Therapeutics (DNLI), Atara Biotherapeutics (ATRA), Audentes Therapeutics (BOLD) and Orchard Therapeutics (ORTX).
What other stocks do shareholders of Momenta Pharmaceuticals own?
Who are Momenta Pharmaceuticals' key executives?
Momenta Pharmaceuticals' management team includes the folowing people:
- Mr. Craig A. Wheeler, Pres, CEO & Exec. Director (Age 59)
- Dr. Ganesh Venkataraman Kaundinya, Co-Founder & Consultant (Age 52)
- Dr. Santiago Arroyo, Chief Medical Officer & Sr. VP of Devel.
- Mr. Bruce A. Leicher, Consultant (Age 63)
- Mr. Scott M. Storer, Consultant
Who are Momenta Pharmaceuticals' major shareholders?
Momenta Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include FMR LLC (15.00%), BlackRock Inc. (13.99%), Perceptive Advisors LLC (2.87%), D. E. Shaw & Co. Inc. (2.64%), RA Capital Management LLC (2.60%) and Norges Bank (1.81%). Company insiders that own Momenta Pharmaceuticals stock include Alejandra Carvajal, Anthony M Manning, Bruce Downey, Bruce Leicher, Craig A Wheeler, Elizabeth Stoner, Ganesh Venkataraman Kaundinya, Ian Fier, Jo Ann Beltramello, Michelle Robertson, Santiago Arroyo, Scott M Storer and Young Kwon. View Institutional Ownership Trends for Momenta Pharmaceuticals.
Which major investors are selling Momenta Pharmaceuticals stock?
MNTA stock was sold by a variety of institutional investors in the last quarter, including Tocqueville Asset Management L.P., New York State Common Retirement Fund, Bank of America Corp DE, KBC Group NV, PNC Financial Services Group Inc., Bank of Montreal Can, MetLife Investment Advisors LLC and Millennium Management LLC. Company insiders that have sold Momenta Pharmaceuticals company stock in the last year include Alejandra Carvajal, Anthony M Manning, Bruce Downey, Bruce Leicher, Craig A Wheeler, Elizabeth Stoner, Ganesh Venkataraman Kaundinya, Ian Fier, Jo Ann Beltramello, Michelle Robertson, Santiago Arroyo and Young Kwon. View Insider Buying and Selling for Momenta Pharmaceuticals.
Which major investors are buying Momenta Pharmaceuticals stock?
MNTA stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Perceptive Advisors LLC, Norges Bank, BlackRock Inc., RA Capital Management LLC, Westfield Capital Management Co. LP, D. E. Shaw & Co. Inc. and Oregon Public Employees Retirement Fund. View Insider Buying and Selling for Momenta Pharmaceuticals.
How do I buy shares of Momenta Pharmaceuticals?
Shares of MNTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Momenta Pharmaceuticals' stock price today?
One share of MNTA stock can currently be purchased for approximately $13.20.
How big of a company is Momenta Pharmaceuticals?
Momenta Pharmaceuticals has a market capitalization of $1.30 billion and generates $75.59 million in revenue each year. The biotechnology company earns $-176,060,000.00 in net income (profit) each year or ($2.03) on an earnings per share basis.
What is Momenta Pharmaceuticals' official website?
How can I contact Momenta Pharmaceuticals?
Momenta Pharmaceuticals' mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-491-9700 or via email at [email protected]
MarketBeat Community Rating for Momenta Pharmaceuticals (NASDAQ MNTA)
MarketBeat's community ratings are surveys of what our community members think about Momenta Pharmaceuticals and other stocks. Vote "Outperform" if you believe MNTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MNTA will underperform the S&P 500 over the long term. You may vote once every thirty days.
